Cited 7 times in
Pembrolizumab-induced Stevens-Johnson Syndrome with Severe Ocular Complications
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김응권 | - |
dc.contributor.author | 김태임 | - |
dc.contributor.author | 전익현 | - |
dc.contributor.author | 서경률 | - |
dc.date.accessioned | 2022-12-22T03:27:34Z | - |
dc.date.available | 2022-12-22T03:27:34Z | - |
dc.date.issued | 2022-08 | - |
dc.identifier.issn | 0927-3948 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191884 | - |
dc.description.abstract | Purpose: To report a unique case of Stevens-Johnson syndrome (SJS) with severe ocular complications induced by pembrolizumab, an immune checkpoint inhibitor. Case presentation: A 64-year-old man with urothelial cancer presented with bilateral corneal epithelial defect and conjunctival pseudo-membrane formation with erythematous patches on the four extremities, abdomen, and back. He had urothelial cancer with multifocal lesions in the renal pelvis and left ureter, and para-aortic metastatic lymph nodes. Accordingly, pembrolizumab treatment was planned. Generalized skin eruption occurred 4 days after the first cycle of pembrolizumab treatment, and ocular symptoms occurred 2 weeks after the first cycle. The patient's symptoms improved after cessation of pembrolizumab treatment and administration of steroids systemically. Conclusions: Immune checkpoint inhibitors, including pembrolizumab, have been developed recently and are widely used in the treatment of various cancers. However, it should be noted that the drugs may cause adverse events such as SJS with severe ocular complications. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Informa Healthcare | - |
dc.relation.isPartOf | OCULAR IMMUNOLOGY AND INFLAMMATION | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized / adverse effects | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Stevens-Johnson Syndrome* / diagnosis | - |
dc.subject.MESH | Stevens-Johnson Syndrome* / etiology | - |
dc.title | Pembrolizumab-induced Stevens-Johnson Syndrome with Severe Ocular Complications | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Ophthalmology (안과학교실) | - |
dc.contributor.googleauthor | Soyoung Ryu | - |
dc.contributor.googleauthor | Ikhyun Jun | - |
dc.contributor.googleauthor | Tae-Im Kim | - |
dc.contributor.googleauthor | Kyoung Yul Seo | - |
dc.contributor.googleauthor | Eung Kweon Kim | - |
dc.identifier.doi | 10.1080/09273948.2021.1896006 | - |
dc.contributor.localId | A00831 | - |
dc.contributor.localId | A01080 | - |
dc.contributor.localId | A03541 | - |
dc.contributor.localId | A01870 | - |
dc.relation.journalcode | J03485 | - |
dc.identifier.eissn | 1744-5078 | - |
dc.identifier.pmid | 33826467 | - |
dc.identifier.url | https://www.tandfonline.com/doi/full/10.1080/09273948.2021.1896006 | - |
dc.subject.keyword | Pembrolizumab | - |
dc.subject.keyword | Stevens–Johnson syndrome | - |
dc.subject.keyword | immune checkpoint inhibitors | - |
dc.subject.keyword | ocular manifestation | - |
dc.subject.keyword | severe ocular complications | - |
dc.contributor.alternativeName | Kim, Eung Kweon | - |
dc.contributor.affiliatedAuthor | 김응권 | - |
dc.contributor.affiliatedAuthor | 김태임 | - |
dc.contributor.affiliatedAuthor | 전익현 | - |
dc.contributor.affiliatedAuthor | 서경률 | - |
dc.citation.volume | 30 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1533 | - |
dc.citation.endPage | 1535 | - |
dc.identifier.bibliographicCitation | OCULAR IMMUNOLOGY AND INFLAMMATION, Vol.30(6) : 1533-1535, 2022-08 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.